PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 18443590-4 2008 Specifically, we found that cis variation at Ephx2 segregated with heart failure and with increased transcript expression, protein expression and enzyme activity, leading to a more rapid hydrolysis of cardioprotective epoxyeicosatrienoic acids. epoxyeicosatrienoic acids 218-243 epoxide hydrolase 2 Rattus norvegicus 45-50 11090543-0 2000 Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. epoxyeicosatrienoic acids 61-86 epoxide hydrolase 2 Rattus norvegicus 0-25 18086949-1 2008 Soluble epoxide hydrolase (sEH) metabolizes epoxyeicosatrienoic acids and represents a novel therapeutic target in cardiovascular disease treatment. epoxyeicosatrienoic acids 44-69 epoxide hydrolase 2 Rattus norvegicus 0-25 18086949-1 2008 Soluble epoxide hydrolase (sEH) metabolizes epoxyeicosatrienoic acids and represents a novel therapeutic target in cardiovascular disease treatment. epoxyeicosatrienoic acids 44-69 epoxide hydrolase 2 Rattus norvegicus 27-30 17639071-1 2007 The P450 eicosanoids epoxyeicosatrienoic acids (EETs) are endogenous lipid mediators produced in the brain by P450 epoxygenases and metabolized through multiple pathways, including soluble epoxide hydrolase (sEH). epoxyeicosatrienoic acids 21-46 epoxide hydrolase 2 Rattus norvegicus 181-206 17639071-1 2007 The P450 eicosanoids epoxyeicosatrienoic acids (EETs) are endogenous lipid mediators produced in the brain by P450 epoxygenases and metabolized through multiple pathways, including soluble epoxide hydrolase (sEH). epoxyeicosatrienoic acids 21-46 epoxide hydrolase 2 Rattus norvegicus 208-211 16157792-1 2005 The present study tested the hypothesis that increasing epoxyeicosatrienoic acids by inhibition of soluble epoxide hydrolase (sEH) would lower blood pressure and ameliorate renal damage in salt-sensitive hypertension. epoxyeicosatrienoic acids 56-81 epoxide hydrolase 2 Rattus norvegicus 99-124 16157792-1 2005 The present study tested the hypothesis that increasing epoxyeicosatrienoic acids by inhibition of soluble epoxide hydrolase (sEH) would lower blood pressure and ameliorate renal damage in salt-sensitive hypertension. epoxyeicosatrienoic acids 56-81 epoxide hydrolase 2 Rattus norvegicus 126-129 34794001-2 2021 The soluble epoxide hydrolase (sEH) hydrolyzes epoxyeicosatrienoic acids (EETs) to dihydroxyeicosatetraenoic acids. epoxyeicosatrienoic acids 47-72 epoxide hydrolase 2 Rattus norvegicus 31-34 7840649-0 1995 Metabolism of epoxyeicosatrienoic acids by cytosolic epoxide hydrolase: substrate structural determinants of asymmetric catalysis. epoxyeicosatrienoic acids 14-39 epoxide hydrolase 2 Rattus norvegicus 43-70 35344709-3 2022 Epoxyeicosatrienoic acids (EETs) were reported to have anti-hypertensive effects, which could be degraded by soluble epoxide hydrolase (sEH), encoded by EPHX2. epoxyeicosatrienoic acids 0-25 epoxide hydrolase 2 Rattus norvegicus 109-134 35344709-3 2022 Epoxyeicosatrienoic acids (EETs) were reported to have anti-hypertensive effects, which could be degraded by soluble epoxide hydrolase (sEH), encoded by EPHX2. epoxyeicosatrienoic acids 0-25 epoxide hydrolase 2 Rattus norvegicus 153-158 35344709-3 2022 Epoxyeicosatrienoic acids (EETs) were reported to have anti-hypertensive effects, which could be degraded by soluble epoxide hydrolase (sEH), encoded by EPHX2. epoxyeicosatrienoic acids 0-25 epoxide hydrolase 2 Rattus norvegicus 136-139 32767848-2 2021 Epoxyeicosatrienoic acids (EETs) are vasodilators; their actions are potentiated by soluble epoxide hydrolase (sEH) inhibition. epoxyeicosatrienoic acids 0-25 epoxide hydrolase 2 Rattus norvegicus 84-109 32767848-2 2021 Epoxyeicosatrienoic acids (EETs) are vasodilators; their actions are potentiated by soluble epoxide hydrolase (sEH) inhibition. epoxyeicosatrienoic acids 0-25 epoxide hydrolase 2 Rattus norvegicus 111-114 33475089-1 2020 Stabilization of epoxyeicosatrienoic acids (EETs) levels via soluble epoxide hydrolase (sEH) deletion or its pharmacological inhibition have been shown to have beneficial effects on inflammation, ischemia, hypertension and diabetes. epoxyeicosatrienoic acids 17-42 epoxide hydrolase 2 Rattus norvegicus 61-86 32736189-2 2020 Epoxyeicosatrienoic acids (EETs) are endogenous anti-inflammatory compounds, which are quickly converted by the soluble epoxide hydrolase (sEH) enzyme into a less active form with decreased biological effects. epoxyeicosatrienoic acids 0-25 epoxide hydrolase 2 Rattus norvegicus 112-137 32736189-2 2020 Epoxyeicosatrienoic acids (EETs) are endogenous anti-inflammatory compounds, which are quickly converted by the soluble epoxide hydrolase (sEH) enzyme into a less active form with decreased biological effects. epoxyeicosatrienoic acids 0-25 epoxide hydrolase 2 Rattus norvegicus 139-142 30644034-5 2019 We found that TPPU and the sEH substrate epoxyeicosatrienoic acids (EETs) protected PC12 cells from the CORT-induced injury by increasing cell viability and inhibiting apoptosis. epoxyeicosatrienoic acids 41-66 epoxide hydrolase 2 Rattus norvegicus 27-30 30728778-2 2019 Previous studies have shown that increasing kidney epoxyeicosatrienoic acids (EETs) by blocking soluble epoxide hydrolase (sEH), an enzyme responsible for EETs degradation, improves the survival rate in CHF induced by aorto-caval fistula (ACF) and attenuates CKD progression. epoxyeicosatrienoic acids 51-76 epoxide hydrolase 2 Rattus norvegicus 96-121 30728778-2 2019 Previous studies have shown that increasing kidney epoxyeicosatrienoic acids (EETs) by blocking soluble epoxide hydrolase (sEH), an enzyme responsible for EETs degradation, improves the survival rate in CHF induced by aorto-caval fistula (ACF) and attenuates CKD progression. epoxyeicosatrienoic acids 51-76 epoxide hydrolase 2 Rattus norvegicus 123-126 28707660-2 2017 The sEH is a key enzyme in metabolism of epoxyeicosatrienoic acids capable of activating endothelial NO-synthase and nitrogen oxide formation, and therefore being vasodilators. epoxyeicosatrienoic acids 41-66 epoxide hydrolase 2 Rattus norvegicus 4-7 29527914-1 2018 We showed recently that increasing kidney epoxyeicosatrienoic acids (EETs) by blocking soluble epoxide hydrolase (sEH), an enzyme responsible for EETs degradation, retarded the development of renal dysfunction and progression of aorto-caval fistula(ACF)-induced congestive heart failure (CHF) in Ren-2 transgenic hypertensive rats (TGR). epoxyeicosatrienoic acids 42-67 epoxide hydrolase 2 Rattus norvegicus 87-112 29527914-1 2018 We showed recently that increasing kidney epoxyeicosatrienoic acids (EETs) by blocking soluble epoxide hydrolase (sEH), an enzyme responsible for EETs degradation, retarded the development of renal dysfunction and progression of aorto-caval fistula(ACF)-induced congestive heart failure (CHF) in Ren-2 transgenic hypertensive rats (TGR). epoxyeicosatrienoic acids 42-67 epoxide hydrolase 2 Rattus norvegicus 114-117 28741242-1 2017 A still growing body of evidence suggests the importance of epoxyeicosatrienoic acids (EETs) in the regulation of inflammatory response; therefore, drugs that stabilize their levels by targeting the soluble epoxide hydrolase (sEH), an enzyme responsible for their metabolism, are currently under investigation. epoxyeicosatrienoic acids 60-85 epoxide hydrolase 2 Rattus norvegicus 199-224 28741242-1 2017 A still growing body of evidence suggests the importance of epoxyeicosatrienoic acids (EETs) in the regulation of inflammatory response; therefore, drugs that stabilize their levels by targeting the soluble epoxide hydrolase (sEH), an enzyme responsible for their metabolism, are currently under investigation. epoxyeicosatrienoic acids 60-85 epoxide hydrolase 2 Rattus norvegicus 226-229 29529602-1 2018 BACKGROUND/AIMS: We found recently that increasing renal epoxyeicosatrienoic acids (EETs) levels by blocking soluble epoxide hydrolase (sEH), an enzyme responsible for EETs degradation, shows renoprotective actions and retards the progression of chronic kidney disease (CKD) in Ren-2 transgenic hypertensive rats (TGR) after 5/6 renal ablation (5/6 NX). epoxyeicosatrienoic acids 57-82 epoxide hydrolase 2 Rattus norvegicus 109-134 29529602-1 2018 BACKGROUND/AIMS: We found recently that increasing renal epoxyeicosatrienoic acids (EETs) levels by blocking soluble epoxide hydrolase (sEH), an enzyme responsible for EETs degradation, shows renoprotective actions and retards the progression of chronic kidney disease (CKD) in Ren-2 transgenic hypertensive rats (TGR) after 5/6 renal ablation (5/6 NX). epoxyeicosatrienoic acids 57-82 epoxide hydrolase 2 Rattus norvegicus 136-139 28332266-1 2017 Epoxyeicosatrienoic acids (EETs) are endogenous ligands that undergo hydrolysis by soluble epoxide hydrolase (sEH). epoxyeicosatrienoic acids 0-25 epoxide hydrolase 2 Rattus norvegicus 83-108 28002622-1 2017 Epoxyeicosatrienoic acids (EETs) are synthesized in astrocytes, and inhibitors of soluble epoxide hydrolase (sEH), which hydrolyzes EETs, reduce infarct volume in ischemic stroke. epoxyeicosatrienoic acids 0-25 epoxide hydrolase 2 Rattus norvegicus 82-107 28002622-1 2017 Epoxyeicosatrienoic acids (EETs) are synthesized in astrocytes, and inhibitors of soluble epoxide hydrolase (sEH), which hydrolyzes EETs, reduce infarct volume in ischemic stroke. epoxyeicosatrienoic acids 0-25 epoxide hydrolase 2 Rattus norvegicus 109-112 28332266-1 2017 Epoxyeicosatrienoic acids (EETs) are endogenous ligands that undergo hydrolysis by soluble epoxide hydrolase (sEH). epoxyeicosatrienoic acids 0-25 epoxide hydrolase 2 Rattus norvegicus 110-113 25663200-3 2016 Soluble epoxide hydrolase (sEH) is an endogenous key enzyme in the metabolic conversion and degradation of P450 eicosanoids called epoxyeicosatrienoic acids (EETs). epoxyeicosatrienoic acids 131-156 epoxide hydrolase 2 Rattus norvegicus 0-25 25663200-3 2016 Soluble epoxide hydrolase (sEH) is an endogenous key enzyme in the metabolic conversion and degradation of P450 eicosanoids called epoxyeicosatrienoic acids (EETs). epoxyeicosatrienoic acids 131-156 epoxide hydrolase 2 Rattus norvegicus 27-30 24471737-2 2014 The aim of the present study was to test the hypothesis that increasing kidney tissue concentrations of epoxyeicosatrienoic acids (EETs) by preventing their degradation to the biologically inactive dihydroxyeicosatrienoic acids (DHETEs) using blockade of soluble epoxide hydrolase (sEH) would attenuate the progression of chronic kidney disease (CKD). epoxyeicosatrienoic acids 104-129 epoxide hydrolase 2 Rattus norvegicus 255-280 26545915-3 2016 Cytochrome P450 (CYP) epoxygenases metabolize arachidonic acid to biologically active eicosanoids called epoxyeicosatrienoic acids (EETs), which are further converted by soluble epoxide hydrolase (sEH) to less bioactive diols. epoxyeicosatrienoic acids 105-130 epoxide hydrolase 2 Rattus norvegicus 170-195 26545915-3 2016 Cytochrome P450 (CYP) epoxygenases metabolize arachidonic acid to biologically active eicosanoids called epoxyeicosatrienoic acids (EETs), which are further converted by soluble epoxide hydrolase (sEH) to less bioactive diols. epoxyeicosatrienoic acids 105-130 epoxide hydrolase 2 Rattus norvegicus 197-200 25986738-1 2015 Soluble epoxide hydrolase (sEH) plays an essential role in chronic kidney disease by hydrolyzing renoprotective epoxyeicosatrienoic acids to the corresponding inactive dihydroxyeicosatrienoic acids. epoxyeicosatrienoic acids 112-137 epoxide hydrolase 2 Rattus norvegicus 0-25 25986738-1 2015 Soluble epoxide hydrolase (sEH) plays an essential role in chronic kidney disease by hydrolyzing renoprotective epoxyeicosatrienoic acids to the corresponding inactive dihydroxyeicosatrienoic acids. epoxyeicosatrienoic acids 112-137 epoxide hydrolase 2 Rattus norvegicus 27-30 25224811-7 2014 Acute BP-lowering effects of sEH inhibition in I3C-induced rats was associated with a marked increase in renal epoxyeicosatrienoic acids to dihydroxyeicosatrienoic acids ratio and acute natriuresis. epoxyeicosatrienoic acids 111-136 epoxide hydrolase 2 Rattus norvegicus 29-32 25224811-9 2014 Our findings show that the acute BP-lowering effect of sEH inhibition in I3C-induced Cyp1a1-Ren-2 transgenic rats is mediated by a substantial increase in intrarenal epoxyeicosatrienoic acids and their natriuretic action without altering intrarenal renin-angiotensin system activity. epoxyeicosatrienoic acids 166-191 epoxide hydrolase 2 Rattus norvegicus 55-58 24471737-2 2014 The aim of the present study was to test the hypothesis that increasing kidney tissue concentrations of epoxyeicosatrienoic acids (EETs) by preventing their degradation to the biologically inactive dihydroxyeicosatrienoic acids (DHETEs) using blockade of soluble epoxide hydrolase (sEH) would attenuate the progression of chronic kidney disease (CKD). epoxyeicosatrienoic acids 104-129 epoxide hydrolase 2 Rattus norvegicus 282-285 24043255-1 2013 Soluble epoxide hydrolase (sEH) diminishes vasodilatory and neuroprotective effects of epoxyeicosatrienoic acids by hydrolyzing them to inactive dihydroxy metabolites. epoxyeicosatrienoic acids 87-112 epoxide hydrolase 2 Rattus norvegicus 0-25 24043255-1 2013 Soluble epoxide hydrolase (sEH) diminishes vasodilatory and neuroprotective effects of epoxyeicosatrienoic acids by hydrolyzing them to inactive dihydroxy metabolites. epoxyeicosatrienoic acids 87-112 epoxide hydrolase 2 Rattus norvegicus 27-30 19969453-1 2010 Inhibition of sEH is hypothesized to lead to an increase in epoxyeicosatrienoic acids resulting in the potentiation of their anti-inflammatory and vasodilatory effects. epoxyeicosatrienoic acids 60-85 epoxide hydrolase 2 Rattus norvegicus 14-17 23725831-1 2013 AIM: To investigate the relationship between cerebroprotection of pinocembrin and epoxyeicosatrienoic acids (EETs) and their regulating enzyme soluble epoxide hydrolase (sEH). epoxyeicosatrienoic acids 82-107 epoxide hydrolase 2 Rattus norvegicus 143-168 23725831-1 2013 AIM: To investigate the relationship between cerebroprotection of pinocembrin and epoxyeicosatrienoic acids (EETs) and their regulating enzyme soluble epoxide hydrolase (sEH). epoxyeicosatrienoic acids 82-107 epoxide hydrolase 2 Rattus norvegicus 170-173 23039246-1 2013 The aim of the present study was to evaluate the hypothesis that the antihypertensive effects of inhibition of soluble epoxide hydrolase (sEH) are mediated by increased intrarenal availability of epoxyeicosatrienoic acids (EETs), with consequent improvement in renal haemodynamic autoregulatory efficiency and the pressure-natriuresis relationship. epoxyeicosatrienoic acids 196-221 epoxide hydrolase 2 Rattus norvegicus 111-136 23039246-1 2013 The aim of the present study was to evaluate the hypothesis that the antihypertensive effects of inhibition of soluble epoxide hydrolase (sEH) are mediated by increased intrarenal availability of epoxyeicosatrienoic acids (EETs), with consequent improvement in renal haemodynamic autoregulatory efficiency and the pressure-natriuresis relationship. epoxyeicosatrienoic acids 196-221 epoxide hydrolase 2 Rattus norvegicus 138-141 22155238-1 2012 The study addressed the hypothesis that soluble epoxide hydrolase (sEH) inhibition, which increases cardiovascular protective epoxyeicosatrienoic acids (EETs), exerts beneficial effects in an established chronic heart failure (CHF) model. epoxyeicosatrienoic acids 126-151 epoxide hydrolase 2 Rattus norvegicus 40-65 22155238-1 2012 The study addressed the hypothesis that soluble epoxide hydrolase (sEH) inhibition, which increases cardiovascular protective epoxyeicosatrienoic acids (EETs), exerts beneficial effects in an established chronic heart failure (CHF) model. epoxyeicosatrienoic acids 126-151 epoxide hydrolase 2 Rattus norvegicus 67-70 22155000-1 2012 Epoxyeicosatrienoic acids (EETs), cytochrome P450-derived metabolites of arachidonic acid, are endogenously produced epoxides that act as substrates for the soluble epoxide hydrolase (sEH). epoxyeicosatrienoic acids 0-25 epoxide hydrolase 2 Rattus norvegicus 157-182 22155000-1 2012 Epoxyeicosatrienoic acids (EETs), cytochrome P450-derived metabolites of arachidonic acid, are endogenously produced epoxides that act as substrates for the soluble epoxide hydrolase (sEH). epoxyeicosatrienoic acids 0-25 epoxide hydrolase 2 Rattus norvegicus 184-187 21266668-1 2011 We hypothesized that perinatal inhibition of soluble epoxide hydrolase (SEH), which metabolizes epoxyeicosatrienoic acids in the arachidonic acid (AA) cascade, with an orally active SEH inhibitor, 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA), would persistently reduce blood pressure (BP) in adult SHR despite discontinuation of AUDA at 4 wk of age. epoxyeicosatrienoic acids 96-121 epoxide hydrolase 2 Rattus norvegicus 45-70 21266668-1 2011 We hypothesized that perinatal inhibition of soluble epoxide hydrolase (SEH), which metabolizes epoxyeicosatrienoic acids in the arachidonic acid (AA) cascade, with an orally active SEH inhibitor, 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA), would persistently reduce blood pressure (BP) in adult SHR despite discontinuation of AUDA at 4 wk of age. epoxyeicosatrienoic acids 96-121 epoxide hydrolase 2 Rattus norvegicus 72-75 21266668-1 2011 We hypothesized that perinatal inhibition of soluble epoxide hydrolase (SEH), which metabolizes epoxyeicosatrienoic acids in the arachidonic acid (AA) cascade, with an orally active SEH inhibitor, 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA), would persistently reduce blood pressure (BP) in adult SHR despite discontinuation of AUDA at 4 wk of age. epoxyeicosatrienoic acids 96-121 epoxide hydrolase 2 Rattus norvegicus 182-185 23232840-1 2013 Epoxyeicosatrienoic acids, substrates for soluble epoxide hydrolase (sEH), exhibit vasodilatory and antihypertrophic activities. epoxyeicosatrienoic acids 0-25 epoxide hydrolase 2 Rattus norvegicus 42-67 23232840-1 2013 Epoxyeicosatrienoic acids, substrates for soluble epoxide hydrolase (sEH), exhibit vasodilatory and antihypertrophic activities. epoxyeicosatrienoic acids 0-25 epoxide hydrolase 2 Rattus norvegicus 69-72 23106500-1 2012 Epoxyeicosatrienoic acids (EETs) and their regulating enzyme soluble epoxide hydrolase (sEH) have been associated with ischemic stroke. epoxyeicosatrienoic acids 0-25 epoxide hydrolase 2 Rattus norvegicus 61-86 23106500-1 2012 Epoxyeicosatrienoic acids (EETs) and their regulating enzyme soluble epoxide hydrolase (sEH) have been associated with ischemic stroke. epoxyeicosatrienoic acids 0-25 epoxide hydrolase 2 Rattus norvegicus 88-91 21039415-1 2011 BACKGROUND AND PURPOSE: Epoxyeicosatrienoic acids (EETs) are cytochrome P450 epoxygenase metabolites of arachidonic acid that are metabolized into dihydroxyepoxyeicosatrienoic acids (DHET) by soluble epoxide hydrolase (sEH). epoxyeicosatrienoic acids 24-49 epoxide hydrolase 2 Rattus norvegicus 192-217 21039415-1 2011 BACKGROUND AND PURPOSE: Epoxyeicosatrienoic acids (EETs) are cytochrome P450 epoxygenase metabolites of arachidonic acid that are metabolized into dihydroxyepoxyeicosatrienoic acids (DHET) by soluble epoxide hydrolase (sEH). epoxyeicosatrienoic acids 24-49 epoxide hydrolase 2 Rattus norvegicus 219-222 19746975-1 2009 Inhibition of soluble epoxide hydrolase (sEH) is hypothesized to lead to an increase in circulating levels of epoxyeicosatrienoic acids, resulting in the potentiation of their in vivo pharmacological properties. epoxyeicosatrienoic acids 110-135 epoxide hydrolase 2 Rattus norvegicus 14-39 19847158-2 2010 Epoxyeicosatrienoic acids are generated by soluble epoxide hydrolase, an enzyme hydrolyzing the epoxide moiety of juvenile hormones in insects, and are endothelium-derived hyperpolarizing factors that induce vessel dilation for cardioprotection. epoxyeicosatrienoic acids 0-25 epoxide hydrolase 2 Rattus norvegicus 43-68 19847158-3 2010 Pharmacological inhibition and genetic ablation of soluble epoxide hydrolase increases the level of epoxyeicosatrienoic acids. epoxyeicosatrienoic acids 100-125 epoxide hydrolase 2 Rattus norvegicus 51-76 19847158-5 2010 Treatment with soluble epoxide hydrolase-selective inhibitors in angiotensin II-infused hypertensive rats increases the level of epoxyeicosatrienoic acids, with attendant decrease in systolic blood pressure. epoxyeicosatrienoic acids 129-154 epoxide hydrolase 2 Rattus norvegicus 15-40 19746975-1 2009 Inhibition of soluble epoxide hydrolase (sEH) is hypothesized to lead to an increase in circulating levels of epoxyeicosatrienoic acids, resulting in the potentiation of their in vivo pharmacological properties. epoxyeicosatrienoic acids 110-135 epoxide hydrolase 2 Rattus norvegicus 41-44 19285984-1 2009 Epoxyeicosatrienoic acids (EETs) are polyunsaturated fatty acids synthesized from arachidonic acid by CYP2J2 epoxygenase and inactivated by soluble epoxide hydrolase (sEH or Ephx2) to dihydroxyeicosatrienoic acids. epoxyeicosatrienoic acids 0-25 epoxide hydrolase 2 Rattus norvegicus 167-170 19285984-1 2009 Epoxyeicosatrienoic acids (EETs) are polyunsaturated fatty acids synthesized from arachidonic acid by CYP2J2 epoxygenase and inactivated by soluble epoxide hydrolase (sEH or Ephx2) to dihydroxyeicosatrienoic acids. epoxyeicosatrienoic acids 0-25 epoxide hydrolase 2 Rattus norvegicus 174-179 19226702-1 2009 OBJECTIVES: The soluble epoxide hydrolase (sEH) metabolizes epoxyeicosatrienoic acids (EETs) to their less active dihydroxy derivatives. epoxyeicosatrienoic acids 60-85 epoxide hydrolase 2 Rattus norvegicus 16-41 19304946-1 2009 Epoxyeicosatrienoic acids (EETs) are potent vasodilators produced from arachidonic acid by cytochrome P-450 (CYP) epoxygenases and metabolized to vicinal diols by soluble epoxide hydrolase (sEH). epoxyeicosatrienoic acids 0-25 epoxide hydrolase 2 Rattus norvegicus 163-188 19304946-1 2009 Epoxyeicosatrienoic acids (EETs) are potent vasodilators produced from arachidonic acid by cytochrome P-450 (CYP) epoxygenases and metabolized to vicinal diols by soluble epoxide hydrolase (sEH). epoxyeicosatrienoic acids 0-25 epoxide hydrolase 2 Rattus norvegicus 190-193 19226702-1 2009 OBJECTIVES: The soluble epoxide hydrolase (sEH) metabolizes epoxyeicosatrienoic acids (EETs) to their less active dihydroxy derivatives. epoxyeicosatrienoic acids 60-85 epoxide hydrolase 2 Rattus norvegicus 43-46 19126686-2 2009 Epoxyeicosatrienoic acids, hydrolyzed and degraded by soluble epoxide hydrolase (sEH), can function as endothelium-derived hyperpolarizing factors to induce dilation of coronary arteries and thus are cardioprotective. epoxyeicosatrienoic acids 0-25 epoxide hydrolase 2 Rattus norvegicus 54-79 19126686-2 2009 Epoxyeicosatrienoic acids, hydrolyzed and degraded by soluble epoxide hydrolase (sEH), can function as endothelium-derived hyperpolarizing factors to induce dilation of coronary arteries and thus are cardioprotective. epoxyeicosatrienoic acids 0-25 epoxide hydrolase 2 Rattus norvegicus 81-84